TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1688989

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg three times a day for 3 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nifedipine without diltiazem
Number of subjects: 6
Study: 453874

Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin in an adhesive base
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 38
Study: 31484031

Group type: EXPERIMENTAL
Intervention: In-home occupational therapy intervention (6 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 59
Study: 29220347

Group type: EXPERIMENTAL
Intervention: Community-wide treatment (CWT)
Number of subjects: 81167

Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT)
Number of subjects: 81167

Group type: COMPARATOR
Intervention: Two rounds of treatment (with two intermittent or consecutive holiday years)
Number of subjects: 81167

Group type: EXPERIMENTAL
Intervention: Four rounds of treatment (CWT or SBT)
Number of subjects: 81167

Group type: EXPERIMENTAL
Intervention: Annual CWT
Number of subjects: 81167

Group type: EXPERIMENTAL
Intervention: SBT arms
Number of subjects: 81167
Study: 26131911

Group type: EXPERIMENTAL
Intervention: cTACE with bevacizumab (5 mg/kg every 2 weeks for 52 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: cTACE with placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: cTACE with bevacizumab
Number of subjects: 40
Study: 23527952

Group type: COMPARATOR
Intervention: hIVIG (0.5 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VINC (0.02 mg/kg)
Number of subjects: 20
Study: 21751372

Group type: EXPERIMENTAL
Intervention: rhGH (2 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 8
Study: 18929352

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA) combined with laser photocoagulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Laser photocoagulation alone (control)
Number of subjects: 22
Study: 16766489

Group type: EXPERIMENTAL
Intervention: Topical 2% niacinamide
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo moisturizer
Number of subjects: 130
Study: 15122537

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (PCC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Problem Solving Skills Training (PSP)
Number of subjects: 31
Study: 11270030

Group type: EXPERIMENTAL
Intervention: Propofol with ketamine (0.5 mg kg‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 22
Study: 9243726

Group type: EXPERIMENTAL
Intervention: No bed rest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Short period of bed rest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Other types of intervention
Number of subjects: 40
Study: 8342756

Group type: EXPERIMENTAL
Intervention: Normal saline 4 ml injected through the epidural needle before catheter passage
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no saline injection)
Number of subjects: 189
Study: 3574424

Group type: COMPARATOR
Intervention: 30 mg of isosorbide dinitrate (single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg of isosorbide dinitrate (twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg of isosorbide dinitrate (three times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg of isosorbide dinitrate (four times daily)
Number of subjects: 12
Study: 29686412

Group type: EXPERIMENTAL
Intervention: Fir honey
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chestnut honey
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Citrus honey
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heather honey
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pine honey
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thyme honey
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose reference
Number of subjects: 11
Study: 26739037

Group type: EXPERIMENTAL
Intervention: CSB Plus supplementation
Number of subjects: 547

Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 547
Study: 24875961

Group type: EXPERIMENTAL
Intervention: Spinal arthrodesis (thoracic or lumbar fusion)
Number of subjects: 1915
Study: 23812339

Group type: EXPERIMENTAL
Intervention: 3-day course of linezolid and meropenem
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 78
Study: 20505594

Group type: EXPERIMENTAL
Intervention: Actisorb (without silver)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Actisorb Silver 220
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrocolloid dressing (control)
Number of subjects: 120
Study: 18512074

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant UFT (400 mg/day for 12 months)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 139
Study: 16809797

Group type: COMPARATOR
Intervention: Ispronicline (TC-1734) single-dose (2-320 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ispronicline (TC-1734) multiple-dose (50, 100, and 200 mg, once daily, x 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ispronicline (TC-1734)
Number of subjects: 0
Study: 14568795

Group type: EXPERIMENTAL
Intervention: 5% PVP-I ear drops, administered topically, 3 drops 3 times daily for 10 days.
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.3% ciprofloxacin ear drops, administered topically, 3 drops 3 times daily for 10 days.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% PVP-I ear drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.3% ciprofloxacin ear drops
Number of subjects: 40
Study: 11798649

Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 ppm NO with helium-oxygen mixture
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 ppm NO with helium-oxygen mixture
Number of subjects: 18
Study: 8740786

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Tamoxifen
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Untreated patients (excluding opposite-breast and skin tumors)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Tamoxifen-treated patients (excluding opposite-breast and skin tumors)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Chemotherapy-treated patients (excluding opposite-breast and skin tumors)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Tamoxifen (excluding opposite-breast and skin tumors)
Number of subjects: 1696
Study: 1826883

Group type: EXPERIMENTAL
Intervention: Intravenous alpha-human ANP (initial bolus of 0.5 micrograms/kg followed by a 21-min maintenance infusion at 0.05 micrograms.kg-1.min-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline intravenous infusion (control group)
Number of subjects: 12
Study: 7040929

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 200 mg/m2 followed by 5-fluorouracil (5-FU) 600 mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 40 mg/m2 followed by 5-fluorouracil (5-FU) 600 mg/m2
Number of subjects: 30
Study: 31350870

Group type: EXPERIMENTAL
Intervention: Topical insulin-liposomal gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 80
Study: 30303973

Group type: EXPERIMENTAL
Intervention: Isometric Core Training (ICT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dynamic Core Training (DCT)
Number of subjects: 19
Study: 26291554

Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 25044402

Group type: EXPERIMENTAL
Intervention: safinamide 50 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: safinamide 100 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: safinamide (both dosages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: safinamide and placebo
Number of subjects: 0
Study: 22475083

Group type: COMPARATOR
Intervention: Immediate test ordering
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Watchful waiting with quality improvement strategy
Number of subjects: 498
Study: 20576162

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional moxibustion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional drug treatment (intra-articular Sodium Hyaluronate injection)
Number of subjects: 0
Study: 18019591

Group type: EXPERIMENTAL
Intervention: Active console video games
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonactive console video games
Number of subjects: 21
Study: 16117450

Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG) application during cardiovascular surgery
Number of subjects: 0
Study: 12125181

Group type: EXPERIMENTAL
Intervention: Plant-derived preparations for symptomatic treatment of obstipation, irritable bowel, and inflammatory bowel disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phytotherapeutic preparations
Number of subjects: 0
Study: 9924589

Group type: EXPERIMENTAL
Intervention: Trivalent oral polio vaccine (TOPV) in Group A (vaccinated at 34-35 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Trivalent oral polio vaccine (TOPV) in Group B (vaccinated at 38-40 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (Group C: term babies vaccinated in the 1st week of life)
Number of subjects: 62
Study: 7987981

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 0
Study: 3338259

Group type: EXPERIMENTAL
Intervention: 1‐[3H]noradrenaline infusion
Number of subjects: 19
Study: 29653120

Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Uncovered self-expandable metal stent (USEMS)
Number of subjects: 158
Study: 26460721

Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Trachway®
Number of subjects: 80
Study: 24967372

Group type: EXPERIMENTAL
Intervention: Action observation (AO) coupled with upper limb training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 67
Study: 22825085

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 338

Group type: COMPARATOR
Intervention: Structured education program
Number of subjects: 338
Study: 21080780

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 2314

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 2314
Study: 18775266

Group type: EXPERIMENTAL
Intervention: NIOX analyser (Group 1, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NIOX-MINO analyser (Group 2, n = 30)
Number of subjects: 60
Study: 15830219

Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Alcohol expectancy (placebo)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 17
Study: 12888589

Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release formulation (1000 mg once daily for five consecutive days)
Number of subjects: 42
Study: 11782036

Group type: EXPERIMENTAL
Intervention: Cox regression with time‐dependent covariates including time elapsed since last observation (TEL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression with time‐dependent covariates
Number of subjects: 0
Study: 9246981

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g single injection)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 40
Study: 8352456

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Olive oil supplementation for 6 months
Number of subjects: 16
Study: 3101777

Group type: EXPERIMENTAL
Intervention: Adenosine (intravenous boluses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aminophylline (antagonist to adenosine)
Number of subjects: 6
Study: 2655625

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 100
Study: 30764699

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with HFpEF
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nondiabetic subjects with HFpEF
Number of subjects: 53
Study: 28089225

Group type: EXPERIMENTAL
Intervention: Individualised treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group treatment
Number of subjects: 90
Study: 26267985

Group type: EXPERIMENTAL
Intervention: High-dose ergocalciferol (double dosage from K/DOQI recommendations)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional-dose ergocalciferol (as recommended by K/DOQI guidelines)
Number of subjects: 68
Study: 22818512

Group type: EXPERIMENTAL
Intervention: Alcohol brief interventions (BIs)
Number of subjects: 1219
Study: 21175612

Group type: EXPERIMENTAL
Intervention: +BRT
Number of subjects: 100

Group type: COMPARATOR
Intervention: -BRT
Number of subjects: 100
Study: 19164441

Group type: EXPERIMENTAL
Intervention: Surgical removal of colloid cysts
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 38
Study: 17280678

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg/day
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 136
Study: 16396714

Group type: COMPARATOR
Intervention: Nailfold capillaroscopy (NFC) in children with MCTD
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nailfold capillaroscopy (NFC) in children with SLE
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nailfold capillaroscopy (NFC) in children with JDM
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nailfold capillaroscopy (NFC) in children with JSSc
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nailfold capillaroscopy (NFC) in children with JIA
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC) in connective tissue diseases
Number of subjects: 118
Study: 11172152

Group type: EXPERIMENTAL
Intervention: Chloroquine treatment
Number of subjects: 176
Study: 9270631

Group type: EXPERIMENTAL
Intervention: Prolonged regimen of prophylaxis with ticarcillin/clavulanate for 2 days and low-dose vancomycin until removal of the intraaortic balloon pump (n = 28)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prolonged regimen of prophylaxis with ticarcillin/clavulanate and low-dose vancomycin (n = 28)
Number of subjects: 53
Study: 8175538

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (45 +/- 3 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inhaled saline (S + HV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hyperventilation (HV)
Number of subjects: 8
Study: 3284271

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg before tracheal intubation, 5 micrograms/kg before skin incision, and 2 micrograms/kg each 15 min during the 1st hour)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 28
Study: 30932053

Group type: EXPERIMENTAL
Intervention: Amyg‐EFP‐NF
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control-EEG-NF
Number of subjects: 180

Group type: COMPARATOR
Intervention: NoNF
Number of subjects: 180
Study: 28329184

Group type: EXPERIMENTAL
Intervention: Tracing by peer health workers
Number of subjects: 5781

Group type: COMPARATOR
Intervention: Not randomly selected (Control)
Number of subjects: 5781
Study: 26216410

Group type: EXPERIMENTAL
Intervention: Embryo transfer at 2 cm distance from the fundal endometrium (DFE)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Embryo transfer at the midpoint of the endometrial cavity length (ECL)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Embryo transfer at 2 cm DFE
Number of subjects: 195

Group type: COMPARATOR
Intervention: Embryo transfer at the midpoint of the ECL
Number of subjects: 195
Study: 23219061

Group type: EXPERIMENTAL
Intervention: Focussed narrative interview
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 21943180

Group type: EXPERIMENTAL
Intervention: Moxibustion plus usual care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 18349212

Group type: EXPERIMENTAL
Intervention: Stimulating catheter (SC) technique
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nonstimulating catheter (NSC) technique
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both SC and NSC techniques
Number of subjects: 82
Study: 16517384

Group type: COMPARATOR
Intervention: Traditional training from experienced instructors
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Augmented feedback on specific biomechanical aspects of spinal manipulation therapy using an instrumented manikin
Number of subjects: 31
Study: 12709737

Group type: EXPERIMENTAL
Intervention: Sirolimus (6 mg loading dose over 48 hours plus 2 mg/day maintenance) + low-dose cyclosporine (8 mg/kg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sirolimus + low-dose cyclosporine
Number of subjects: 12
Study: 11010949

Group type: EXPERIMENTAL
Intervention: Mixed-fiber diet (50% soluble fiber and 50% insoluble fiber)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insoluble-fiber diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fiber-free diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mixed-fiber diet
Number of subjects: 8
Study: 8797619

Group type: EXPERIMENTAL
Intervention: Heparinized central venous catheters (n = 13)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control central venous catheters (n = 19)
Number of subjects: 55
Study: 1518121

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) administered at 10 mg/10 mg/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) administered at 20 mg/20 mg/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) administered at 31.3 mg/31.3 mg/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) administered in various doses (5.2 mg/5.2 mg to 31.3 mg/31.3 mg/kg)
Number of subjects: 52
Study: 6375540

Group type: EXPERIMENTAL
Intervention: simethicon ‐ pankreatin
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: lysin‐vasopressin
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: filling of the stomach with soup and erect position
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: prone position
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: dimethicon
Number of subjects: 750
Study: 31367741

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omadacycline and Moxifloxacin
Number of subjects: 0
Study: 30551561

Group type: EXPERIMENTAL
Intervention: Upgraded case payment (intervention group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: County level hospital (intervention group)
Number of subjects: 0
Study: 27461049

Group type: EXPERIMENTAL
Intervention: ¡Cocinar Para Su Salud! (n = 34), a culturally based 9-session program (24 hours over 12 weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ¡Cocinar Para Su Salud! (n = 34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (n = 36, written dietary recommendations for breast cancer survivors)
Number of subjects: 70
Study: 24423431

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/d
Number of subjects: 83

Group type: COMPARATOR
Intervention: 400 IU vitamin D3/d
Number of subjects: 83
Study: 22280547

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 41
Study: 20209395

Group type: EXPERIMENTAL
Intervention: Early appendicectomy for appendicular mass
Number of subjects: 506

Group type: COMPARATOR
Intervention: Conservative management for appendicular mass
Number of subjects: 506
Study: 19033604

Group type: EXPERIMENTAL
Intervention: Tango dance program (10 weeks, 40 hours, 2 hours twice a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Walking program (10 weeks, 40 hours, 2 hours twice a week)
Number of subjects: 30
Study: 16298597

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 19

Group type: COMPARATOR
Intervention: Wash-out period (discontinuing diltiazem)
Number of subjects: 19
Study: 12431802

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GHRP-6
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 15
Study: 10413263

Group type: EXPERIMENTAL
Intervention: Decision training (complex instruction, variable practice, reduced delayed feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioural training (simple-to-complex instruction, variable practice, abundant feedback)
Number of subjects: 0
Study: 7585841

Group type: EXPERIMENTAL
Intervention: ICI 204,636 (25 to 250 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2186067

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback with adjunctive relaxation training (TBF)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback plus cognitive therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Pseudomeditation as an ostensible attention‐placebo control
Number of subjects: 116

Group type: COMPARATOR
Intervention: Headache monitoring
Number of subjects: 116
Study: 657994

Group type: EXPERIMENTAL
Intervention: Tinidazole (55.5 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole (52.0 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 100